Rockwell Medical (RMTI) Cash from Operations Growth (1y) (2011 - 2026)
Rockwell Medical (RMTI) Cash from Operations Growth (1y) (2011 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.96 Bn | 43.00 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.23 Bn | 39.58 Bn | 2.15 Bn | 81.06% |
| 3 | Zoetis | 31.76 Bn | 30.08 Bn | 1.05 Bn | 8.26% |
| 4 | Takeda Pharmaceutical | 28.68 Bn | 22.88 Bn | 5.10 Bn | -46.22% |
| 5 | United Therapeutics | 22.27 Bn | 19.61 Bn | 683.80 Mn | 63.59% |
| 6 | Viatris | 18.69 Bn | 17.81 Bn | 1.46 Bn | 73.78% |
| 7 | Neurocrine Biosciences | 15.56 Bn | 15.17 Bn | 935.80 Mn | 33.73% |
| 8 | Elanco Animal Health | 11.78 Bn | 11.25 Bn | 798.00 Mn | 16.88% |
| 9 | Dr Reddys Laboratories | 10.13 Bn | 9.97 Bn | - | - |
| 10 | Rockwell Medical | 29.77 Mn | 4.98 Mn | 3.24 Mn | 14.59% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 14.59% |
| Mar 31, 2026 | 94.26% |
| Dec 31, 2025 | 160.12% |
| Sep 30, 2025 | -131.58% |
| Jun 30, 2025 | 30.86% |
| Mar 31, 2025 | -46.51% |
| Dec 31, 2024 | 2,111.63% |
| Sep 30, 2024 | 213.91% |
| Jun 30, 2024 | 182.87% |
| Mar 31, 2024 | 38.60% |
| Dec 31, 2023 | 61.61% |
| Sep 30, 2023 | -240.56% |
| Jun 30, 2023 | 70.53% |
| Mar 31, 2023 | 60.49% |
| Dec 31, 2022 | 98.76% |
| Sep 30, 2022 | 84.42% |
| Jun 30, 2022 | -19.56% |
| Mar 31, 2022 | 21.48% |
| Dec 31, 2021 | -5.33% |
| Sep 30, 2021 | -43.86% |